ADAP adaptimmune.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

The market price of Adaptimmune (ADAP), as confirmed by the chart, demonstrates an EV/EBITDA multiple of . The company's growth relies on the launch of Tecelra in the US market and the development of its solid tumor platform. However, the costly sales launch and scaling challenges remain significant hurdles. Meanwhile, the business maintains an asset-light model by fully outsourcing production and trials.

For T-cell therapy leader Adaptimmune (ADAP), this indicator compares the total enterprise value, including debt, with earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA trend over time, an investor assesses the capitalization efficiency of breakthrough genetic developments relative to the debt load, where an increase in the metric signals either business expansion or an asset revaluation.